HIV/AIDS is a worldwide pandemic afflicting 40 million people, and currently there is no cure. The proposed research is to develop a new reporter cell line to facilitate the discovery of novel anti-HIV drugs. This prospective reporter cell system will employ a Rev-dependent lentiviral vector, which has been shown previously to be highly specific to HIV infection. This novel system will greatly facilitate the development of a novel cell- based drug screening platform. Additionally, by employing two reporters this system can be used in multiple assay formats and would be amenable to high-throughput screens for antiretroviral compounds.

Public Health Relevance

This NIH R03 Small Research Program grant is to develop a new research methodology, namely, the development of a new Rev-dependent cell line to screen for anti-HIV drugs. HIV infection causes AIDS that afflicted approximately 40 million people globally. This proposed research will facilitate the development of new therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Research Grants (R03)
Project #
5R03AI093157-02
Application #
8296270
Study Section
AIDS Molecular and Cellular Biology Study Section (AMCB)
Program Officer
Miller, Roger H
Project Start
2011-07-05
Project End
2013-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
2
Fiscal Year
2012
Total Cost
$70,745
Indirect Cost
$20,745
Name
George Mason University
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
077817450
City
Fairfax
State
VA
Country
United States
Zip Code
22030